Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease-Reference-Cited by-同舟云学术

Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease

Published:2019-07 Issue:2 Volume:150 Page:218-230
ISSN:0022-3042
Container-title:Journal of Neurochemistry
language:en
Short-container-title:J. Neurochem.

Author:

García‐Ayllón María‐Salud¹²³^ORCID,Monge‐Argilés José‐Antonio⁴⁵,Monge‐García Victoria⁶,Navarrete Francisco²,Cortés‐Gómez Maria‐Angeles¹²,Sánchez‐Payá José⁵⁷,Manzanares Jorge²,Gasparini‐Berenguer Ruth⁴,Leiva‐Santana Carlos⁴,Sáez‐Valero Javier²³⁵

Affiliation:

1. Unidad de Investigación, Hospital General Universitario de Elche, FISABIO Elche Spain

2. Instituto de Neurociencias de Alicante, Universidad Miguel Hernández‐CSIC Sant Joan d’Alacant Spain

3. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Sant Joan d’Alacant Spain

4. Neurology Department University General Hospital of Alicante Alicante Spain

5. Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) Alicante Spain

6. Rehabilitation Service University General Hospital of Alicante Spain

7. Preventive Medicine Service University General Hospital of Alicante Alicante Spain

Funder

European Regional Development Fund

Instituto de Salud Carlos III

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jnc.14719

Reference41 articles.

1. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

2. Revised Criteria for Mild Cognitive Impairment: Validation within a Longitudinal Population Study

3. Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study

4. Diagnostic value of cerebrospinal fluid alpha‐synuclein in dementia with Lewy body;Bousiges O.;Geriatr. Psychol. Neuropsychiatr. Vieil.,2018

5. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiopep-2 modified dual drug-loaded liposomes with brain targeting functionality mitigate Alzheimer’s disease-related symptoms in APP/PS-1 mice;Journal of Drug Targeting;2023-05-25

2. Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease;Frontiers in Neurology;2023-05-24

3. Alzheimer's disease therapeutics;Privileged Scaffolds in Drug Discovery;2023

4. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease;Alzheimer's Research & Therapy;2022-12-31

5. Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects;Revue Neurologique;2022-05